title: Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis.
abstract: The pharmacokinetics of fleroxacin and its metabolites following a single oral dose of fleroxacin 400mg were examined in 6 healthy subjects and 24 patients with various degrees of renal insufficiency. Plasma and urine samples, collected at various times after administration, were assayed by high performance liquid chromatography (HPLC). In healthy subjects, Cmax was 6.8 +/- 0.7 mg/L; tmax = about 1h, t1/2 = 14 +/- 2h, total clearance = 4.86 +/- 0.72 L/h and the percentage of unchanged fleroxacin excreted in urine in 48 hours was 48 +/- 4% (HPLC). Plasma concentrations of metabolites were very low and accounted for no more than 5% of the levels of unchanged fleroxacin. In uraemic patients Cmax did not change, whatever the degree of renal failure; tmax was increased in patients with a glomerular filtration rate below 0.6 L/h, and Vd/f was independent of the severity of renal failure. These data suggest that bioavailability of the drug is unchanged. In uraemic patients t1/2 was prolonged and AUC multiplied by a factor of 2 to 3. A linear relationship was found between total and renal clearances of fleroxacin and creatinine clearance. Accumulation of N-demethyl-fleroxacin and N-oxide-fleroxacin was very high in uraemic patients, due to slow formation of these metabolites and decreased urinary elimination. Dialysance of fleroxacin and of its metabolites was approximately 3.6 to 4.8 L/h. These findings suggest that fleroxacin dosage may need to be reduced in patients with severe renal disease; in haemodialysed patients, treated every 2 days, a single dose of fleroxacin 400mg is recommended at the end of each dialysis session.
authors.affiliation: Clinical Pharmacy, Hôpital Bicètre, Paris, France.
authors.forename: E
authors.initials: E
authors.lastname: Singlas
authors.forename: A
authors.initials: A
authors.lastname: Leroy
authors.forename: E
authors.initials: E
authors.lastname: Sultan
authors.forename: M
authors.initials: M
authors.lastname: Godin
authors.forename: B
authors.initials: B
authors.lastname: Moulin
authors.forename: A M
authors.initials: AM
authors.lastname: Taburet
authors.forename: M
authors.initials: M
authors.lastname: Dhib
authors.forename: J P
authors.initials: JP
authors.lastname: Fillastre
mesh_terms: D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000378:metabolism / Q000493:pharmacokinetics*; D002939:Ciprofloxacin / Q000031:analogs & derivatives* / Q000378:metabolism / Q000493:pharmacokinetics; D005260:Female; D016576:Fleroxacin; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis
chemical_list: D000890:Anti-Infective Agents; D002939:Ciprofloxacin; D016576:Fleroxacin